Public-registry site landscape for NCT07686263, a Schizophrenia study sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07686263 (registry record) |
| Sponsor | Karuna Therapeutics, Inc., a Bristol Myers Squibb company |
| Condition(s) | Schizophrenia |
| Phase | PHASE3 |
| Listed sites | 61 |
| Site countries | United States, Argentina, Bulgaria, Czechia, Denmark, Poland, Romania, Spain, United Kingdom |
Eichor generates a preliminary site-risk snapshot for NCT07686263 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →